161Tb与177Lu标记生长抑素类似物在临床前环境中耐受性的比较
本研究在免疫健全小鼠中比较161Tb与177Lu标记的DOTA-LM3和DOTATATE的耐受性。基于生物分布数据计算剂量学,评估20 MBq和100 MBq给药后血细胞计数、骨髓涂片、血浆参数及器官组织学。结果显示生长抑素受体拮抗剂所致血液学变化较激动剂更明显,但161Tb标记药物在各自177Lu类似物推荐活性水平下应安全。
要点
- 20 MBq的161Tb标记DOTA-LM3或DOTATATE耐受良好,无主要血液学变化。
- 100 MBq给药后第10天淋巴细胞较未治疗对照低40-50%,与所用核素无关。
- 第56天所有血细胞计数均在正常范围,组织学异常轻微。
核心结论
- 用生长抑素受体拮抗剂治疗的小鼠血液学变化较用生长抑素受体激动剂者更明显。
- 尽管161Tb较177Lu传递的吸收剂量更高,161Tb标记的DOTA-LM3和DOTATATE在各自177Lu类似物推荐活性水平下应安全。
研究设计与样本
- 在免疫健全小鼠中基于放射性肽的生物分布数据进行剂量学计算。
- 在小鼠给药后第10、28和56天评估血细胞计数,并设未治疗对照。
- 比较20 MBq与100 MBq的161Tb标记放射性肽,并与177Lu标记对应物比较。
- 研究终点评估骨髓涂片、血浆参数和器官组织学。
主要发现
- 生长抑素受体拮抗剂的吸收器官剂量通常高于生长抑素受体激动剂,且161Tb高于177Lu。
- 20 MBq的161Tb标记DOTA-LM3或DOTATATE耐受良好,无主要血液学变化。
- 100 MBq的161Tb和177Lu标记生长抑素类似物影响血细胞计数。
- 第10天,无论所用核素如何,治疗小鼠淋巴细胞较未治疗对照低40-50%。
- 同一时间点,生长抑素受体拮抗剂给药后血小板计数低30-50%(p < 0.05)、红细胞计数低6-12%,而生长抑素受体激动剂的变化较不明显。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: [177Lu]Lu-DOTATATE is an established somatostatin receptor (SSTR) agonist for the treatment of metastasized neuroendocrine neoplasms, while the SSTR antagonist [177Lu]Lu-DOTA-LM3 has only scarcely been employed in clinics. Impressive preclinical data obtained with [161Tb]Tb-DOTA-LM3 in tumor-bearing mice indicated the potential of terbium-161 as an alternative to lutetium-177. The aim of the present study was to compare the tolerability of 161Tb- and 177Lu-based DOTA-LM3 and DOTATATE in immunocompetent mice. METHODS: Dosimetry calculations were performed based on biodistribution data of the radiopeptides in immunocompetent mice. Treatment-related effects on blood cell counts were assessed on Days 10, 28 and 56 after application of [161Tb]Tb-DOTA-LM3 or [161Tb]Tb-DOTATATE at 20 MBq per mouse. These radiopeptides were also applied at 100 MBq per mouse and the effects compared to those observed after application of the 177Lu-labeled counterparts. Bone marrow smears, blood plasma parameters and organ histology were assessed at the end of the study. RESULTS: The absorbed organ dose was commonly higher for the SSTR antagonist than for the SSTR agonist and for terbium-161 over lutetium-177. Application of a therapeutic activity level of 20 MBq [161Tb]Tb-DOTA-LM3 or [161Tb]Tb-DOTATATE was well tolerated without major hematological changes. The injection of 100 MBq of the 161Tb- and 177Lu-based somatostatin analogues affected the blood cell counts, however. The lymphocytes were 40-50% lower in treated mice compared to the untreated controls on Day 10 irrespective of the radionuclide employed. At the same timepoint, thrombocyte and erythrocyte counts were 30-50% and 6-12% lower, respectively, after administration of the SSTR antagonist (p < 0.05) while changes were less pronounced in mice injected with the SSTR agonist. All blood cell counts were in the normal range on Day 56. Histological analyses revealed minimal abnormalities in the kidneys, liver and spleen of treated mice. No correlation was observed between the organ dose and frequency of the occurrence of abnormalities. CONCLUSION: Hematologic changes were more pronounced in mice treated with the SSTR antagonist than in those treated with the SSTR agonist. Despite the increased absorbed dose delivered by terbium-161 over lutetium-177, [161Tb]Tb-DOTA-LM3 and [161Tb]Tb-DOTATATE should be safe at activity levels that are recommended for their respective 177Lu-based analogues.
引用
- Busslinger SD, Mapanao AK, Kegler K, et al. Comparison of the tolerability of 161Tb- and 177Lu-labeled somatostatin analogues in the preclinical setting. Eur J Nucl Med Mol Imaging. 2024. PMID: 39046521. doi:10.1007/s00259-024-06827-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。